Search Results - Xueyan Liang

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer by Xueyan Liang, Xiaoyu Chen, Huijuan Li, Yan Li

Connect to this object online.

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer by Xueyan Liang, Xiaoyu Chen, Xiaoyu Chen, Huijuan Li, Yan Li

Connect to this object online.

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis by Xueyan Liang, Xiaoyu Chen, Huijuan Li, Xiaoxia Liu, Yan Li

Connect to this object online.

Optimal Chinese herbal injections plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A systematic review and Bayesian network meta-analysis by Yan Li, Jiaxi Xi, Sitong Guo, Henghai Su, Xiaoyu Chen, Xueyan Liang

Connect to this object online.

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis by Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, Xiaoyu Chen

Connect to this object online.

Panax notoginseng preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis by Xiuge Tang, Mingdi Huang, Junsong Jiang, Xueyan Liang, Xianshu Li, Ruqing Meng, Lingyuan Chen, Yan Li

Connect to this object online.